Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
78 hedge funds and large institutions have $75.1M invested in Sorrento Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 29 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
16% more call options, than puts
Call options by funds: $313K | Put options by funds: $270K
20% less funds holding
Funds holding: 97 → 78 (-19)
49% less capital invested
Capital invested by funds: $147M → $75.1M (-$72.2M)
66% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.19M |
| 2 |
Renaissance Technologies
New York
|
+$2.32M |
| 3 |
Citigroup
New York
|
+$1.81M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.74M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$808K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.91M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.96M |
| 4 |
IP
Intellectus Partners
San Francisco,
California
|
-$2.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.6M |
SRNE Hedge Fund Activity: Q4 2018 in Review
78 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2018, worth a combined $75.1M — down 49% from $147M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SRNE and 10 opened new positions — a net loss of 19 holders — while 17 trimmed existing stakes and 34 added.
The largest buyer was Morgan Stanley, adding an estimated $6.19M. The largest seller was Invesco, exiting entirely with an estimated $6.02M sold.
- 78 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2018, down from 97 in Q3 2018.
- Funds reported $75.1M of Sorrento Therapeutics, Inc. stock for Q4 2018, down 49% quarter-over-quarter.
- 10 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2018 and 29 closed out, a net change of -19 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2018 was Morgan Stanley, an estimated $6.19M added.
- The largest Sorrento Therapeutics, Inc. seller in Q4 2018 was Invesco, an estimated $6.02M sold.
Based on aggregated 13F filings for Q4 2018.